Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 2
2016 1
2017 3
2018 8
2019 5
2020 5
2021 13
2022 12
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU).
Saouli A, Ruffion A, Dariane C, Barret E, Fiard G, Hankard GF, Créhange G, Roubaud G, Beauval JB, Brureau L, Renard-Penna R, Gauthé M, Baboudjian M, Ploussard G, Rouprêt M. Saouli A, et al. Among authors: gauthe m. Cancers (Basel). 2023 Nov 20;15(22):5485. doi: 10.3390/cancers15225485. Cancers (Basel). 2023. PMID: 38001745 Free PMC article. Review.
Response to Letter to the Editor From Jagannath and Mayilvaganan: "FCH-PET/CT in Primary Hyperparathyroidism With Discordant/Negative MIBI Scintigraphy and Ultrasonography".
Koumakis E, Gauthé M, Martinino A, Sindayigaya R, Delbot T, Wartski M, Clerc J, Roux C, Borderie D, Cochand-Priollet B, Cormier C, Gaujoux S. Koumakis E, et al. Among authors: gauthe m. J Clin Endocrinol Metab. 2024 Feb 20;109(3):e1318-e1319. doi: 10.1210/clinem/dgad615. J Clin Endocrinol Metab. 2024. PMID: 37846771 No abstract available.
[18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study.
Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, Tamayo P, Robin P, García Vicente AM, Bouyeure AC, Bailliez A, Rodríguez-Fernández A, Mahmoud SB, Vallejo-Casas JA, Maksud P, Merlin C, Blanc-Durand P, Drouet C, Tissot H, Vierasu I, Vander Borght T, Boos E, Chossat F, Hodolic M, Rousseau C. Oprea-Lager DE, et al. Among authors: gauthe m. Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3439-3451. doi: 10.1007/s00259-023-06301-5. Epub 2023 Jun 21. Eur J Nucl Med Mol Imaging. 2023. PMID: 37341747 Free PMC article. Clinical Trial.
Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461.
von Eyben R, Kapp DS, Hoffmann MA, Soydal C, Uprimny C, Virgolini I, Tuncel M, Gauthé M, von Eyben FE. von Eyben R, et al. Among authors: gauthe m. Cancers (Basel). 2023 Feb 7;15(4):1035. doi: 10.3390/cancers15041035. Cancers (Basel). 2023. PMID: 36831697 Free PMC article.
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M, Roubaud G, Fromont G, Gauthé M, Beauval JB, Barret E, Brureau L, Créhange G, Dariane C, Fiard G, Mathieu R, Ruffion A, Rouprêt M, Renard-Penna R, Sargos P, Ploussard G; Prostate Cancer Committee of the French Association of Urology. Baboudjian M, et al. Among authors: gauthe m. World J Urol. 2023 Aug;41(8):2033-2041. doi: 10.1007/s00345-022-04239-1. Epub 2022 Dec 9. World J Urol. 2023. PMID: 36484817 Review.
Phase III Study of 18F-PSMA-1007 Versus 18F-Fluorocholine PET/CT for Localization of Prostate Cancer Biochemical Recurrence: A Prospective, Randomized, Crossover Multicenter Study.
Olivier P, Giraudet AL, Skanjeti A, Merlin C, Weinmann P, Rudolph I, Hoepping A, Gauthé M. Olivier P, et al. Among authors: gauthe m. J Nucl Med. 2023 Apr;64(4):579-585. doi: 10.2967/jnumed.122.264743. Epub 2022 Nov 23. J Nucl Med. 2023. PMID: 36418170 Free PMC article. Clinical Trial.
Heterogeneity of contemporary grade group 4 prostate cancer in radical prostatectomy specimens.
Martini A, Touzani A, Beauval JB, Ruffion A, Olivier J, Gasmi A, Dariane C, Thoulouzan M, Barret E, Brureau L, Créhange G, Fiard G, Gauthé M, Renard-Penna R, Roubaud G, Sargos P, Roumiguié M, Timsit MO, Mathieu R, Villers A, Rouprêt M, Fromont G, Ploussard G; CC-AFU, Cancerology Committee of the Association Française d’Urologie. Martini A, et al. Among authors: gauthe m. World J Urol. 2022 Dec;40(12):2931-2937. doi: 10.1007/s00345-022-04202-0. Epub 2022 Nov 7. World J Urol. 2022. PMID: 36342512
53 results